J. Ming

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Joon Sang Lee, H. Linden, S. Chandarlapaty, 2022, Nature Communications.

Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader

E. Jouannot, C. Aubert, L. Besret, 2020, EJNMMI Research.